Neo-Candimyk® (Itraconazole)

Neo-Candimyk® (itraconazole) is used to manage invasive fungal infections across several disease families.

• Candidiasis: effective for systemic and invasive Candida infections.
• Aspergillosis: treats chronic and invasive forms of Aspergillus infection.
• Blastomycosis: used for severe Blastomyces dermatitidis infections.
• Histoplasmosis: indicated for disseminated Histoplasma capsulatum disease.
• Systemic mycoses: provides therapy for a broad spectrum of deep‑tissue fungal infections.

• Itraconazole inhibits the fungal enzyme lanosterol 14α‑demethylase, a cytochrome P450 isoform essential for converting lanosterol to ergosterol. By blocking ergosterol synthesis, the drug disrupts fungal cell membrane integrity, leading to impaired growth and eventual cell death of susceptible fungi.

Adverse reactions may occur with itraconazole therapy and are categorized by frequency.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional episodes of emesis.
• Abdominal pain: discomfort or cramping in the stomach area.
• Headache: transient mild to moderate headache.
• Rash: skin redness or itching.
• Taste disturbance: altered taste perception.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Cardiac failure: worsening of pre‑existing heart conditions.
• Severe hypotension: marked drop in blood pressure.
• Visual disturbances: blurred vision or photophobia.
• Anaphylaxis: rare but life‑threatening allergic reaction.

Before initiating therapy, clinicians should consider several safety measures.

• Liver monitoring: assess baseline liver function and repeat periodically.
• Cardiac assessment: use caution in patients with heart failure.
• Drug interaction review: evaluate concomitant medications for potential interactions.
• Hypersensitivity: discontinue if signs of allergic reaction appear.
• Dose adjustment: modify dosing in patients with hepatic impairment.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Itraconazole has a notable potential for pharmacokinetic interactions.

Major Interactions (Avoid)

• Rifampin: induces metabolism, reducing itraconazole exposure.
• Carbamazepine: strong enzyme inducer, markedly lowers drug levels.
• St. John’s wort: herbal inducer that decreases efficacy.
• Ketoconazole: competitive inhibition may increase toxicity.
• HIV protease inhibitors (e.g., ritonavir): can cause dangerous plasma level spikes.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Phenytoin: can lower itraconazole concentrations.
• Macrolide antibiotics (e.g., erythromycin): may increase levels.
• Calcium channel blockers (e.g., verapamil): may raise plasma concentrations.
• Oral contraceptives: efficacy may be reduced, advise alternative contraception.